IMMUNOHISTOCHEMICAL EXPRESSION OF ANDROGEN RECEPTOR IN TRIPLE NEGATIVE BREAST CARCINOMA AT ARMED FORCES INSTITUTE OF PATHOLOGY, RAWALPINDI

Código QR

IMMUNOHISTOCHEMICAL EXPRESSION OF ANDROGEN RECEPTOR IN TRIPLE NEGATIVE BREAST CARCINOMA AT ARMED FORCES INSTITUTE OF PATHOLOGY, RAWALPINDI

Mostrar otras versiones (1)

Objective: To determine the frequency of immunohistochemical expression of androgen receptor in triple negative breast carcinoma. Study Design: Cross sectional study. Duration and Place of Study: This study included 30 cases confirmed as triple negative breast carcinoma at Armed Forces Insti...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Amna Ameer, Farhan Akhtar, Hafeez Ud Din, Rabia Ahmad
Formato:	article
Lenguaje:	EN
Publicado:	Army Medical College Rawalpindi 2021
Materias:	androgen receptor triple negative breast carcinoma breast carcinoma hormone receptors Medicine R Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/af9a107239794dbea4953729b3644642
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

IMMUNOHISTOCHEMICAL EXPRESSION OF ANDROGEN RECEPTOR IN TRIPLE NEGATIVE BREAST CARCINOMA AT ARMED FORCES INSTITUTE OF PATHOLOGY, RAWALPINDI
por: Amna Ameer, et al.
Publicado: (2021)

Prognostic value of androgen receptor expression in triple negative breast carcinomas: personal experience and comments on a review about “Triple-negative breast cancer: treatment challenges and solutions” by Collignon et al
por: Ieni A, et al.
Publicado: (2016)

Novel Mechanisms of Tumor Promotion by the Insulin Receptor Isoform A in Triple-Negative Breast Cancer Cells
por: Veronica Vella, et al.
Publicado: (2021)

Triple-negative breast cancer: treatment challenges and solutions
por: Collignon J, et al.
Publicado: (2016)

ASSESSMENT OF STROMAL AND INTRA-EPITHELIAL TUMOR INFILTRATING LYMPHOCYTES IN COLORECTAL CARCINOMA AT ARMED FORCES INSTITUTE OF PATHOLOGY
por: Amna Ameer, et al.
Publicado: (2021)

Triple-negative apocrine carcinoma as a rare cause of a breast lump in a Syrian female: a case report and review of the literature
por: Sawsan Ismail, et al.
Publicado: (2021)

Resultados del tratamiento del cáncer de mama, Programa Nacional de Cáncer del Adulto
por: Castillo,César del SM., et al.
Publicado: (2017)

Secreted indicators of androgen receptor activity in breast cancer pre-clinical models
por: Toru Hanamura, et al.
Publicado: (2021)

Prognostic and clinicopathological values of tissue expression of MFAP5 and ITM2A in triple-negative breast cancer: an immunohistochemical study
por: Abdulwahab Abuderman, et al.
Publicado: (2020)

Stem Cells and Androgen Receptor in Human Periapical Periodontitis
por: Rodríguez,H, et al.
Publicado: (2011)

Establishment and validation of an individualized macrophage-related gene signature to predict overall survival in patients with triple negative breast cancer
por: Peng Su, et al.
Publicado: (2021)

Effect of Concurrent Training and Supplementation with β-Hydroxy- β-Methylbutyirate (HMB) on the Prostate: Alterations in the Androgen Receptor and Inflammation
por: Baptista,Danilo Bianchini, et al.
Publicado: (2018)

Costo beneficio del estudio de diseminación en estadios I y II del cáncer de mama
por: Camacho N,Jamile, et al.
Publicado: (2003)

Palmatine sensitizes chemoresistant triple negative breast cancer cells via efflux inhibition of multidrug resistant protein 1.
por: Selase Ativui, et al.
Publicado: (2021)

Real-World Data from a Refractory Triple-Negative Breast Cancer Cohort Selected Using a Clinical Data Warehouse Approach
por: Hana Kim, et al.
Publicado: (2021)

Triple-Negative Breast Cancer: Assessing the Role of Immunohistochemical Biomarkers on Neoadjuvant Treatment
por: da Silva JL, et al.
Publicado: (2021)

The Clinical Value of Chemotherapy Combined With Capecitabine in Triple-Negative Breast Cancer—A Meta-Analysis
por: Zilin Zhang, et al.
Publicado: (2021)

Trop-2 Therapy in Metastatic Triple-Negative Breast Cancer in Italy: Clinical Opportunity and Regulatory Pitfalls
por: Sara Bravaccini, et al.
Publicado: (2021)

Expression of Programmed Cell Death-1 (PD-1) and Its Ligand (PD-L1) in Breast Cancers and Its Association with Clinicopathological Parameters: A Study from North India
por: Anoushika Mehan, et al.
Publicado: (2021)

Encapsulating Halofuginone Hydrobromide in TPGS Polymeric Micelles Enhances Efficacy Against Triple-Negative Breast Cancer Cells
por: Zuo R, et al.
Publicado: (2021)

Cáncer de mama en mujeres adultas mayores, características clínicas e histopatológicas y resultados del tratamiento con intención curativa
por: Sánchez R,Cesar, et al.
Publicado: (2013)

Current advances in biomarkers for targeted therapy in triple-negative breast cancer
por: Fleisher B, et al.
Publicado: (2016)

IMMUNOREGULATION OF BLOOD SERUM ESTRADIOL AND PROGESTERONE LEVELS IN POSTMENOPAUSAL WOMEN
por: A. N. Glushkov, et al.
Publicado: (2019)

Inhibition of Vasculogenic Mimicry and Angiogenesis by an Anti-EGFR IgG1-Human Endostatin-P125A Fusion Protein Reduces Triple Negative Breast Cancer Metastases
por: Seung-Uon Shin, et al.
Publicado: (2021)

A Combined Nomogram Model to Predict Disease-free Survival in Triple-Negative Breast Cancer Patients With Neoadjuvant Chemotherapy
por: Bingqing Xia, et al.
Publicado: (2021)

Self-Assembled Dual-Targeted Epirubicin-Hybrid Polydopamine Nanoparticles for Combined Chemo-Photothermal Therapy of Triple-Negative Breast Cancer
por: Li X, et al.
Publicado: (2020)

Antiangiogenic therapy for breast cancer with triple negative phenotype
por: Inna P. Ganshina, et al.
Publicado: (2021)

Role of PTEN, PI3K, and mTOR in Triple-Negative Breast Cancer
por: Mirjana Prvanović, et al.
Publicado: (2021)

Molecular-Genetic Portrait of Breast Cancer with Triple Negative Phenotype
por: Marina K. Ibragimova, et al.
Publicado: (2021)

Cellular uptake mechanism and comparative evaluation of antineoplastic effects of paclitaxel–cholesterol lipid emulsion on triple-negative and non-triple-negative breast cancer cell lines
por: Ye J, et al.
Publicado: (2016)

Identifying the Effect of Ursolic Acid Against Triple-Negative Breast Cancer: Coupling Network Pharmacology With Experiments Verification
por: Yubao Zhang, et al.
Publicado: (2021)

Androgen Receptor Signaling in Prostate Cancer and Therapeutic Strategies
por: Aasems Jacob, et al.
Publicado: (2021)

Response to FEC Chemotherapy and Oncolytic HSV-1 Is Associated with Macrophage Polarization and Increased Expression of S100A8/A9 in Triple Negative Breast Cancer
por: Alyssa Vito, et al.
Publicado: (2021)

Neighborhood disadvantage and individual-level life stressors in relation to breast cancer incidence in US Black women
por: Lauren E. Barber, et al.
Publicado: (2021)

Non-Coding RNAs Associated With Radioresistance in Triple-Negative Breast Cancer
por: Alberto Aranza-Martínez, et al.
Publicado: (2021)

Testosterone activates glucose metabolism through AMPK and androgen signaling in cardiomyocyte hypertrophy
por: Troncoso,Mayarling Francisca, et al.
Publicado: (2021)

Cytochrome 4Z1 Expression is Associated with Unfavorable Survival in Triple-Negative Breast Cancers
por: Al-saraireh YM, et al.
Publicado: (2021)

ARNTL2 is a Prognostic Biomarker and Correlates with Immune Cell Infiltration in Triple-Negative Breast Cancer
por: Wang X, et al.
Publicado: (2021)

Terapia endocrina neoadyuvante en cáncer de mama, una alternativa de tratamiento e investigación
por: Acevedo,Francisco, et al.
Publicado: (2013)

CDX-2, MUC-2 and B-catenin as intestinal markers in pure mucinous carcinoma of the breast
por: García-Labastida,Laura, et al.
Publicado: (2014)